TP和GP方案治疗晚期非小细胞肺癌的临床观察

目的观察TP方案和GP方案对晚期非小细胞肺癌（NSCLC）的疗效和毒副反应。方法分析43例晚期接受化疗的NSCLC患者资料,其中Ⅲ期NSCLC患者27例,占62.8%,Ⅳ期NSCLC患者16例,占37.2%。总结接受的TP组和GP组至少接受2个周期以上。结果 TP和GP总的有效率分别为40.9%和38.1%。不良反应均在可耐受的范围。结论 TP和GP方案均对晚期NSCLS有效且安全,可作为晚期初治NSCLC的一线化疗方案。

Clinical Observation of Chemotherapy on Advanced Non-small Cell Lung Cancer Patients with TP and GP

Objective To explore the efficacy and toxic reaction of TP and GP on advanced stage non-small cell lung cancer（NSCLC）.Methods The clinic data of 43 patients with NSCLC was collected and analyzed,which included 27 cases（62.8%） in stage Ⅲ and 16 patiences（37.2%） in stage Ⅳ.All the patients had accepted the intravenous chemotherapy of TP or GP for 2 cycles at least.The Response rates（RR）,clinical Response rates（CR＋PR＋SD）,1-year survival rate and toxicity were evaluated.Results The total effective rate of TP and GP for advanced NSCLC were 40.9% in TP group and 38.1% in GP group.The adverse effects of two regiments were little and tolerable.Conclusion Regiments of TP and GP are safe and effective methods in the treatment of advanced stage NSCLC.They could be the first regiment of chemotherapy in advanced stage NSCLC.